- Home
- MTLS vs ATYR Comparison
MTLS vs ATYR Comparison
Compare MTLS & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTLS
- ATYR
- Stock Information
- Founded
- MTLS 1990
- ATYR 2005
- Country
- MTLS Belgium
- ATYR United States
- Employees
- MTLS N/A
- ATYR N/A
- Industry
- MTLS Computer Software: Prepackaged Software
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MTLS Technology
- ATYR Health Care
- Exchange
- MTLS Nasdaq
- ATYR Nasdaq
- Market Cap
- MTLS 316.0M
- ATYR 306.2M
- IPO Year
- MTLS 2014
- ATYR 2015
- Fundamental
- Price
- MTLS $5.40
- ATYR $5.22
- Analyst Decision
- MTLS
- ATYR Strong Buy
- Analyst Count
- MTLS 0
- ATYR 6
- Target Price
- MTLS N/A
- ATYR $20.20
- AVG Volume (30 Days)
- MTLS 86.5K
- ATYR 2.5M
- Earning Date
- MTLS 07-30-2025
- ATYR 08-12-2025
- Dividend Yield
- MTLS N/A
- ATYR N/A
- EPS Growth
- MTLS 43.31
- ATYR N/A
- EPS
- MTLS 0.17
- ATYR N/A
- Revenue
- MTLS $291,295,936.00
- ATYR N/A
- Revenue This Year
- MTLS $6.42
- ATYR $960.85
- Revenue Next Year
- MTLS $8.33
- ATYR $1,283.47
- P/E Ratio
- MTLS $32.22
- ATYR N/A
- Revenue Growth
- MTLS 6.16
- ATYR N/A
- 52 Week Low
- MTLS $3.93
- ATYR $1.42
- 52 Week High
- MTLS $9.69
- ATYR $5.98
- Technical
- Relative Strength Index (RSI)
- MTLS 51.84
- ATYR 62.87
- Support Level
- MTLS $5.37
- ATYR $5.02
- Resistance Level
- MTLS $5.65
- ATYR $5.98
- Average True Range (ATR)
- MTLS 0.18
- ATYR 0.45
- MACD
- MTLS -0.02
- ATYR -0.04
- Stochastic Oscillator
- MTLS 34.27
- ATYR 52.94
About MTLS Materialise NV
Materialise NV is a provider of 3D printing services. The products and services of the group are organized in three segments: Medical segment, which develops and delivers medical software solutions, medical devices, and other related products and services; Software segment, which develops and delivers additive manufacturing software solutions and related services; and Manufacturing segment, which delivers 3D printed products and related services. Its geographical segments are the United States, the Americas (excluding the USA), Belgium, Germany, France, Switzerland, the United Kingdom, Italy, the Netherlands, Other Europe, and the Asia Pacific.
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.